Unit:
Κατεύθυνση Σακχαρώδης Διαβήτης και ΠαχυσαρκίαLibrary of the School of Health Sciences
Author:
Papadopoulou Vasiliki
Supervisors info:
Τίγκας Στυλιανός, Επίκουρος Καθηγητής, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων
Τεντολούρης Νικόλαος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Τατσιώνη Αθηνά, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων
Original Title:
Η γλυκιωμένη αλβουμίνη και η φρουκτοζαμίνη ως δείκτες γλυκαιμικού ελέγχου σε άτομα με σακχαρώδη διαβήτη
Translated title:
Glycated albumin and fructosamine as markers of glycemic control in patients with diabetes mellitus
Summary:
Diabetes mellitus is a chronic metabolic disease that presents high global incidence. Glycosylated hemoglobin has been for years the gold standard method for a long-term glycaemia control and diabetic patients monitoring, and is related with many diabetes complications. However, HbA1c presents certain limitations in its clinical utility and liability, mostly in reference with conditions affecting hemoglobin, glucose daily fluctuations and the long-term period it reflects.
Many of these restrictions can be adequately covered by two other glycosylated plasma proteins, fructosamine (FA) and its higher glycated portion, glycated albumin (GA). These biomarkers reflect more accurately rapid changes in plasma glucose, hypoglycemias and postprandial hyperglycemia. GA and FA are not affected by hemoglobin, although mainly GA depends on albumin metabolic changes.
This review summarizes the studies regarding these methods of glycaemia evaluation, how they are produced through glycosylation, their biochemical status and laboratory measurement. It also discusses the diseases and pathological conditions GA and FA are useful, such as pregnancy and kidney disease.
Main subject category:
Health Sciences
Keywords:
Glycated Albumin, Fructosamine, Diabetes Mellitus
Number of references:
137
